Imaging Lymphoma With F-18 Fluorodeoxyglucose PET-CT: What Should Be Known About Normal Variants, Pitfalls, and Artifacts?

Mboyo Di Tamba Vangu* and Jaleelat I. Momodu

Department of Nuclear Medicine and Molecular Imaging, Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand, Johannesburg, South Africa

18F fluorodeoxyglucose ([F-18] FDG) PET-CT has gained popularity in the management of many types of malignancies. Today, imaging patients with lymphoma using [F-18] FDG PET-CT not only is considered as a state-of-the-art tool but also has taken a central place for therapeutic decisions. In fact, accurate staging at diagnosis is imperative to prevent under treatment of individuals with advanced disease. In Hodgkin’s lymphoma, in particular, the current role of interim [F-18] FDG PET imaging goes beyond speculations in the adaptation of different therapeutic strategies. Therefore, the use of such a critical imaging modality should go hand in hand with sound interpretation that provides accurate results. As the number patients referred for PET-CT continues to increase, imaging specialists should remain aware of the inherent limitations linked to the integrated imaging system that may introduce potential pitfalls related to the machine or the administered [F-18] FDG. Knowledge of the normal physiologic biodistribution of [F-18] FDG, its physiologic variants, and of all the potential pitfalls and artifacts is paramount to avoid misinterpretation. Recognition of the limitations of [F-18] FDG PET-CT will increase the confidence of practicing clinicians on the modality and impact positively on the management of patients. In this article, we will review the normal physiological variants, technical artifacts, and diagnostic pitfalls in lymphoma. Highlighting the limitations of [F-18] FDG PET-CT imaging should warn interpreting specialists to find measures that mitigate them and improve reporting results.

Keywords: FDG, Hodgkin, lymphoma, non-Hodgkin, PET/CT, pitfalls, variants

INTRODUCTION

The popularity gained by positron emission tomography-computed tomography (PET-CT) with the use of 18F-fluorodeoxyglucose ([F-18] FDG) in oncology for the management of malignancies is not to demonstrate anymore. In individuals affected with lymphoma, the modality is today at the center of both staging and therapy decision. PET-CT is currently the imaging standard technique.
FIGURE 1 | Altered biodistribution. FDG PET maximum intensity projection (MIP) image demonstrates diffuse increased muscular uptake in a patient who admits having a meal about an hour before coming for injection despite the knowledge of preparation for study.

NORMAL DISTRIBUTION

[F-18] FDG is used in oncology imaging as an analog of glucose, and most malignant tumors are known to have increased glycolysis. Normal tissues and sites of inflammation also utilize glucose, thus making FDG a non-specific tracer of malignant tissue. Although the mechanism of uptake of [F-18] FDG is beyond the aim of this paper, it should be remembered that hyperglycemia may interfere with tumor uptake due to competition with glucose (8). Routinely, patients are asked to fast for at least 4–6 h prior to [F-18] FDG administration to minimize the impact of insulin levels and therefore improve tumor uptake (9). Since most patients fast for 4–6 h, it is sensible to advise them to take clear water before administration of FDG. However, glucose levels are routinely checked, and it is acceptable to inject FDG if levels are 200 mg/dl or less. Generally, imaging is performed at about 60 min after tracer administration to allow enough tumor uptake. Essentially, FDG uptake is seen throughout the body with variable degrees in different organs. The brain exhibits high uptake, the myocardium may still show high uptake despite fasting of 4–6 h, and urinary activity of excreted FDG is seen as high activity in kidneys, ureters, and bladder. Hence, patients are requested to empty their bladder before starting acquisition of images.

VARIANTS, ARTIFACTS, AND PITFALLS

It is important to recognize physiological variations of FDG uptake, technical artifacts, and potential pitfalls that may impact the interpretation of PET-CT in lymphoma. Because the usual imaging acquisition is similar for most malignant diseases and often includes the head down to mid-thigh region, physiological variants and technical artifacts are also similar. Variations on physiological uptake of FDG are well recognized (1–3), and some may mimic pathological findings.

Uptake in skeletal muscle is one of the most common alterations that should be recognized and is mainly due to either exercise or unwanted muscle activation from stress that increases FDG accumulation and impacts interpretation, as it may mimic pathology (Figure 1). Patients should therefore be advised to avoid exercise both before administration of [F18] FDG and in period following injection to prevent muscle uptake. Situations that will have similarly increased muscle uptake include non-fasting individuals, diabetic patients on insulin, and patients on corticosteroid treatment (1, 10, 11, 12).

In patients with lower body mass and during winter seasons or cold days, patterns of symmetrical FDG uptake are common in the neck, supraclavicular, and paraspinous regions (Figure 2). The culprit for these patterns of FDG uptake has been identified as brown fat, a known organ of thermogenesis (11). Of the two forms of fat in the human body, white and brown, the latter generates heat when a human body is exposed to cold (1).
While the abovementioned three anatomical regions seem to be the prominent areas of visualized uptake in brown fat, attention should be paid to other areas of potential brown fat uptake that include the axilla, intercostal spaces, paracolic and parahepatic spaces, periphenic space, and around the large vessels in the mediastinum (1). One should remember that decreasing adrenergic stimulation may minimize FDG accumulation in brown fat. Pharmacological intervention with oral diazepam or administration of propranolol and limiting exposure of patients to cold temperature are the proposed measures to decrease brown fat uptake (1, 11).

Knowledge of common artifacts may assist the interpreting physicians to decrease the number of studies that may require to be repeated and in the understanding of altered FDG distribution. Extravasation of FDG at the injection site must be recognized because a small amount of such activity may mimic a subcutaneous focal pathology or be drained in the adjacent lymph node station. However, a large amount of FDG extravasation in soft tissue may cause a significant artifact (Figure 3), and such great extravasation may interfere with the accuracy of calculated standard uptake values (SUVs) of the pathological areas of interest, as they may not reflect the true dosage of injected activity in the blood (11).

Motion artifacts may also occur due to patients changing position during PET acquisition. Because most current CTs part of integrated systems are fast, patients’ motion during PET acquisition will result in misregistration (1, 11–14). Although respiratory gating in modern PET-CT scanners will minimize misregistration, attention must be paid near the diaphragm...
where significant motion will cause the FDG to project over anatomical areas that may mimic pathology. Correction of any misregistration is possible if recognized and with the use of current software packages that allow adjustment of date and correct alignment error (Figure 4).

Movements from patients may also cause ring artifacts that result from misregistration of transmission (CT) and emission (PET) scanning. Attenuation-corrected artifacts are not less common and must be recognized. Metal implants and objects carried by patients and oral or intravenous contrast may create areas of false increased FDG uptake due to attenuation correction artifacts (Figure 5). It is thus advised to review the data set of non-attenuated images, as the artifacts are usually readily recognized as the false increased uptake disappears (1, 13, 14).

Like stated earlier on, PET-CT plays a crucial role in staging and treatment monitoring in lymphoma. Although HD and DLBC NHL are highly FDG avid and almost pose no problem in the use of [F18] FDG PET-CT for staging and evaluation of treatment response, other histological subtypes of NHL that
FIGURE 6 | Thymus activity from a 12-year-old female who was diagnosed with Hodgkin’s lymphoma (HD) from cervical lymph nodes. She was referred for a staging, and FDG/PET image (A) shows normal uptake in the thymus (solid arrow) with the expected inverted “V” shape that is consistent with a variant of normal. Both CT (B) and fused PET-CT (C) confirmed the nature of visualized change in the anterior mediastinum.

FIGURE 7 | A 50-year-old female diagnosed with Hodgkin’s lymphoma (HD) and received 3 cycles of R-CHOP. She was referred for interim evaluation of therapy. FDG PET MIP image shows evidence of marrow stimulation with diffuse increased uptake throughout the red marrow due to response to treatment. Patterns of diffuse FDG at interim or immediately following completion of therapy should not be interpreted as bone marrow involvement.

have less FDG uptake must be known. They usually include primary cutaneous anaplastic large T-cell lymphoma, extranodal marginal zone lymphoma, and small lymphocytic lymphoma (3, 15). In such conditions, the interpreting physician should alert the referring physician that the evaluated subtype is less or not FDG avid, thus a follow-up study to assess response to therapy may be misleading and most likely not useful (11). Main pitfalls in lymphoma are due to thymic, bone marrow, splenic, and reactive uptake (1, 11). It is crucial to recognize thymic hyperplasia or physiologic activity in a young patient with FDG uptake in the anterior mediastinum (Figure 6). Although a normal variant in a young individual, the phenomenon is common and expected as a reaction to chemotherapy. Patients with myeloid hyperplasia following granulocyte colony-stimulating factor (G-CSF) therapy have diffuse bone marrow uptake. Similarly, during or immediately after chemotherapy, bone marrow activation also shows diffuse FDG uptake (Figure 7). While these instances may obscure possible bone marrow infiltration, diffuse uptake should not be interpreted as due to bone marrow involvement. When a focal bone marrow uptake is seen in the pelvis, particularly in the posterior ilium, one must first consider the history of BMB as the cause of single and focal uptake. Like bone marrow, the spleen will show diffuse increased uptake in post G-CSF or patients with concurrent infectious conditions. Lymphoma is primarily a nodal disease, and studies performed to evaluate response should be assessed with caution for residual and/or progression of disease. Mimic of lymph nodes may erroneously impact management, as the presence or absence of active nodes may alter treatment decision (Figure 8).

Today, with the advent of SARS-CoV-2 (COVID19) infections, we are seeing an emergence of new entities that may mimic nodal pathology in the axilla and pulmonary infiltration. Patients with recent COVID-19 vaccine show active axillary lymph nodes on the side of the shoulder that received the vaccine (Figure 9). Immediately post COVID-19 infection, ground-glass
opacification may be active with FDG uptake in the lungs (Figure 10).

Interpreting physicians must be aware of all these potential changes and their impact on PET-CT reports in patients with HD and NHL. Furthermore, the introduction of digital PET machines has resulted in increased sensitivity with a relative increased FDG uptake as compared to analog systems. In a recent prospective single-center study, Constantino et al. (16) showed higher lesion SUVs with digital systems in a head-to-head comparison with analog systems. However, when they applied specific protocols’ reconstructions, the relative difference was minimized between analog and digital PET system (16).

CONCLUSION
As PET-CT takes the center of imaging patients with lymphoma and the number of referrals is continuously increasing, it becomes imperative to recognize its limitations to improve patients’ management. In this paper, we highlighted the normal variants, artifacts,
and pitfalls related to lymphoma that should improve confidence of reporting physicians while reducing potential reporting misinterpretations.

**AUTHOR CONTRIBUTIONS**

MV: conception, write up, images collection, and revision. JM: write up and images collection. All authors contributed to the article and approved the submitted version.

**ACKNOWLEDGMENTS**

All images used in this paper are from the archive of our digital uMI550 PET/CT. I thank our radiography staff for the assistance and dedication in retrieving these images from our local PACS (HOROS), particularly Mariam Marlie and Rene Mosley.
REFERENCES

1. Lin E, Alavi A, PET. and PET/CT. A clinical guide 3rd Ed. New York: Thieme. (2019). doi: 10.1055/b-0039-166610
2. Weber M, Jentzen W, Hofferber R, Herrmann K, Fendler WP, Rischpler C et al. Evaluation of F18-FDG PET/CT images acquired with a reduced scan time duration in lymphoma patients using the digital biograph vision. BMC Cancer. (2021) 21:62. doi: 10.1186/s12885-020-07723-2
3. Cheson BD, Kostakoglu L, FDG. for early response assessment in lymphomas: Part 1-Hodgkin lymphoma. Oncology. (2017) (1):45—52
4. Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Armand P, Bello CM, et al. NCCN clinical guidelines in oncology. Hodgkin lymphoma. Natl Compr Canc Netw. (2020) 18:755–81 doi: 10.6004/jnccn.2020.0026
5. Zelenetz AD, Abramson JS, Adavani RH, Andreadis CB, Byrd JC, Czuczman MS et al. NCCN clinical guidelines in oncology: non-hodgkin lymphomas. Natl Compr Canc Netw. (2010) 8:288nc. Ne doi: 10.6004/jnccn.2010.0021
6. Kirby AM, Mikhaeel NG. The role of FDG PET in the management of lymphoma: what is the evidence base? Nucl Med Commun. (2007) (5):335eel doi: 10.1097/MNM.0b013e3280895e23
7. Berthet L, Cochet A, Kanoun S, Berriero-Riedinger A, Humbert O, Toubléau M et al. In newly diagnosed diffused large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy. J Nucl Med. (2013) (8):1244A. doi: 10.2967/jnumed.112.114710
8. Wahl RL. Henry CA, Ethier SP. Serum glucose: effects on tumour and normal tissue accumulation of 2-[F-18]-fluoro-2-deoxy-D-glucose in rodents with mammary carcinoma. Radiology. (1992) 183:643CA, doi: 10.1148/radiology.183.3.1584912
9. Torizuka T, Fisher SJ, Wahl RL. Insulin induced hypoglycaemia decreases uptake of 2-[F-18]-fluoro-2-deoxy-D-glucose into experimental mammary carcinoma. Radiology. (1997) 203:169Aer doi: 10.1148/radiology.203.1.9122387
10. Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics. (1999) 19:61.ai doi: 10.1148/radiographics.19.1.g9ja0761
11. Viglianti BL, Wong Kk, Gross MD, Wale DJ. Common pitfalls in oncologic FDG PET/CT Imaging. J Am Osteopath Coll Radiol. (2018) 7:5a17.
12. Cook GJR, Wegner EA, Folgeman I. Pitfalls and artifacts in 18F-FDG PET and PET/CT oncologic imaging. Semin Nucl Med. (2004) 34:122r E doi: 10.1053/j.semnuclmed.2003.12.003
13. Sureshbabu W, Mawlawi O. PET/CT imaging artifacts. J Nucl Med Technol. (2005) 33:156–61.
14. Simpson DL, Bui-Mansfield T, Bank KP. FDG PET/CT: artifacts and pitfalls. Contemp Diagn Radiol. (2017) 40:1–7 doi: 10.1097/01.CDR.0000513008.49307.b7
15. Weiler-Sagie M, Bushelev O, Epelbaum R, Dann El,Haim N, Avivi I, et al. (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med. (2010) 51:25M, B doi: 10.2967/jnumed.109.067892
16. Constantino CS, Oliveira FPM, Silva M, Oliveira C, Castanheira JC, Silva o, et al. Are lesion features reproducible between 18F-FDG PET/CT images when acquired on analog or digital PET/CT scanners? Eur Radiol. (2021) 31:3071age doi: 10.1007/s00330-020-07390-8

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Vangu and Momodu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.